$0.963
-0.013 (-1.37%)Zum Schluss
ALLR-News
ALLR-Events
Allarity Signs First CLIA Certified Contract
Allarity announced its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy. CLIA certification is a U.S. regulatory requirement for laboratories performing testing on specimens from humans, such as blood, body fluids, and tissue. The agreement represents the first commercial validation of Allarity's CLIA-certified laboratory services strategy following the company's receipt of CLIA certification in July. Under the agreement, Allarity will provide a European biotechnology company with development, validation and related laboratory services to support implementation of a proprietary precision oncology predictive device for use in the United States. Successful completion of the program could lead to ongoing commercial testing and CLIA-related service revenues.
Allarity Therapeutics Updates on Drug Response Predictor Technology Advances
Allarity Therapeutics provided an update on recent advances in its proprietary Drug Response Predictor technology, patent portfolio and in-house laboratory capabilities that strengthen its ability to drive stenoparib's clinical development while expanding external partnership opportunities. Allarity Therapeutics was established on its proprietary patient selection technology-the Drug Response Predictor, DPR. Recent patent awards coupled with the CLIA certification of Allarity's in-house lab allow the company to extend the utility of the test as a companion diagnostic test and to retain sole control of that clinical test. These developments extend the commercial viability of both stenoparib and the stenoparib-DRP test.
Allarity Therapeutics Expands Medical Lab Capabilities
Allarity Therapeutics announced that it has expanded the capabilities of its in-house medical laboratory to include proteomics and cell line research. The new capabilities build on the laboratory's existing transcriptomics research and CLIA clinical testing services and are expected to support Allarity in several areas.
Valion Bio Appoints Lisa Wolf as President and COO
Valion Bio (VBIO) announced strategic changes to its management team and Board of Directors designed to accelerate execution across its clinical and commercial initiatives and position the Company for its next phase of growth. The Company's Board of Directors has unanimously appointed Lisa Wolf to the expanded roles of President and COO. Ms. Wolf will continue to serve as CFO and will assume executive leadership of the Company following the departure of former CEO Michael Handley. The Company also announces the recent appointments of Thomas Jensen and Jared Malbin as directors to its Board. Malbin currently serves as COO of Lucid Capital Markets. Jensen currently serves as CEO, Co-Founder and Director of Nasdaq-listed Allarity Therapeutics (ALLR).
Allarity Receives Patent Allowance Notice for Stenoparib Companion Diagnostic
Allarity announced that the United States Patent and Trademark Office has issued a notice of allowance for its patent application covering the company's DRP companion diagnostic specific to stenoparib. Importantly, this notice of allowance covers multiple claims and represents a major step in Allarity's global strategy to expand and protect the commercial potential of stenoparib when selecting patients using its proprietary stenoparib DRP test. The patent is expected to be formally granted within three months, subject to standard administrative procedures and would provide exclusivity at least into 2039 for stenoparib when used in concert with the DRP as a companion diagnostic.
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.